Heat Biologics, Inc. (HTBX)
-NasdaqCM | Prev Close: | 12.60 |
|---|
| Open: | N/A |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 25.50 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | N/A - N/A |
|---|
| 52wk Range: | 9.01 - 13.50 |
|---|
| Volume: | 0 |
|---|
| Avg Vol (3m): | 73,435 |
|---|
| Market Cap: | 78.04M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- HEAT BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or PrincipalEDGAR Online(Tue, Oct 1)
- InPlay: Heat Biologics files IND for bladder cancer product candidateBriefing.com(Tue, Oct 1)
- Heat Biologics Files IND for Bladder Cancer Product CandidateMarketwired(Tue, Oct 1)
- Heat Biologics: An Undervalued Cancer Vaccine Play That Leaves Considerable Room For Upsideat Seeking Alpha(Mon, Sep 30)
- Heat Biologics Appoints Louis C. Bock to Board of DirectorsMarketwired(Wed, Sep 25)
- Heat Biologics, Inc. to Present at Aegis Capital Corp. 2013 Healthcare ConferenceMarketwired(Thu, Sep 19)
- Heat Biologics initiated with a Buy at Aegistheflyonthewall.com(Wed, Sep 18)
- Coverage initiated on Heat Biologics by Aegis CapitalBriefing.com(Wed, Sep 18)
- HEAT BIOLOGICS, INC. Files SEC form 10-Q, Quarterly ReportEDGAR Online(Thu, Sep 5)
- Heat Biologics, Inc. Announces Partial Exercise of Underwriters' Over-Allotment OptionMarketwired(Wed, Sep 4)
- Heat Biologics, Inc. Announces Partial Exercise of Underwriters' Over-Allotment OptionMarketwired(Tue, Aug 13)
- U.S. IPO Recap: 11 Deals Prince In Busiest Week Since November 2007, 8 Companies Set Termsat Seeking Alpha(Tue, Jul 30)
- Heat Biologics, Inc. Announces Closing of Initial Public Offering of 2,500,000 Shares of Common StockMarketwired(Mon, Jul 29)
- Agios IPO jumps, 2 others decline in debutsAP(Wed, Jul 24)
- NASDAQ Welcomes Heat Biologics (NASDAQ:HTBX) to The NASDAQ Stock MarketGlobeNewswire(Wed, Jul 24)
Reports
- No Reports available for HTBX at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.90 |
|---|
| Quarterly EPS Est
(Sep-13)
: | -0.23 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Heat Biologics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of various cellular therapeutic vaccines for a range of cancers and infectious diseases.
View More
0.41%